Van Cutsem, Eric and Hoff, P. M. and Harper, P. and Bukowski, R. M. and Cunningham, D. and Dufour, P. and Graeven, U. and Lokich, J. and Madajewicz, S. and Maroun, J. A. and Marshall, J. L. and Mitchell, E. P. and Perez-Manga, G. and Rougier, P. and Schmiegel, W. and Schoelmerich, Juergen and Sobrero, A. and Schilsky, R. L. (2004) Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. BRITISH JOURNAL OF CANCER, 90 (6). pp. 1190-1197. ISSN 0007-0920, 1532-1827
Full text not available from this repository. (Request a copy)Abstract
This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic colorectal cancer (mCRC) treated in two identically designed phase III studies. A total of 1207 patients with previously untreated mCRC were randomised to either oral capecitabine (1250 mg m(-2) twice daily, days 1 - 14 every 21 days; n = 603) or intravenous (i.v.) bolus 5-fluorouracil/leucovorin (5-FU/LV; Mayo Clinic regimen; n = 604). Capecitabine demonstrated a statistically significant superior response rate compared with 5-FU/LV (26 vs 17%; P<0.0002). Subgroup analysis demonstrated that capecitabine consistently resulted in superior response rates (P<0.05), even in patient subgroups with poor prognostic indicators. The median time to response and duration of response were similar and time to progression (TTP) was equivalent in the two arms (hazard ratio (HR) 0.997, 95% confidence interval (CI) 0.885-1.123, P=0.95; median 4.6 vs 4.7 months with capecitabine and 5-FU/LV, respectively). Multivariate Cox regression analysis identified younger age, liver metastases, multiple metastases and poor Karnofsky Performance Status as independent prognostic indicators for poor TTP. Overall survival was equivalent in the two arms (HR 0.95, 95% Cl 0.84-1.06, P = 0.48; median 12.9 vs 12.8 months, respectively), Capecitabine results in superior response rate, equivalent TTP and overall survival, an improved safety profile and improved convenience compared with i.v. 5-FU/LV as first-line treatment for MCRC. For patients in whom fluoropyrimidine monotherapy is indicated, capecitabine should be strongly considered. Following encouraging results from phase I and II trials, randomised trials are evaluating capecitabine in combination with irinotecan, oxaliplatin and radiotherapy. Capecitabine is a suitable replacement for i.v. 5-FU as the backbone of colorectal cancer therapy.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | METASTATIC COLORECTAL-CANCER; FLUOROURACIL PLUS LEUCOVORIN; 1ST-LINE TREATMENT; FLUOROPYRIMIDINE CARBAMATE; IRINOTECAN; OXALIPLATIN; THERAPY; REGIMEN; PHARMACOKINETICS; INFUSION; capecitabine; colorectal cancer; fluoropyrimidine; efficacy; oral |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 26 Jul 2021 08:18 |
| Last Modified: | 26 Jul 2021 08:18 |
| URI: | https://pred.uni-regensburg.de/id/eprint/37863 |
Actions (login required)
 |
View Item |
